Canada markets closed

Panbela Therapeutics, Inc. (PBLA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7400+0.0799 (+12.10%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.6601
Open0.6999
Bid0.7400 x 900
Ask0.7799 x 1400
Day's Range0.6825 - 0.7400
52 Week Range0.5910 - 3.3500
Volume38,759
Avg. Volume38,788
Market Cap15.373M
Beta (5Y Monthly)0.04
PE Ratio (TTM)N/A
EPS (TTM)-0.9160
Earnings DateAug 09, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • GlobeNewswire

    Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic

    In vitro studies determined that SBP-101 reduced cellular viability across a broad range of cancer cell types, with an exceptionally strong reduction in ovarian adenocarcinoma viability resulting in a 42% increase in median survival in VDID8+ ovarian cancer mouse model MINNEAPOLIS, June 28, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc.- (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced

  • GlobeNewswire

    Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.

    MINNEAPOLIS, June 16, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today announced the closing of its acquisition of Cancer Prevention Pharmaceuticals, Inc. (CPP), a private clinical stage company developing therapeutics to reduce the risk and recurrence of cancer and rare diseases, for a combination of stock and future milestone payments. The combined entity will focus o

  • GlobeNewswire

    Panbela Provides Business Update and Reports Q1 2022 Financial Results

    MINNEAPOLIS, May 12, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today provides a business update and reports financial results for the quarter ended March 31, 2022. Management is hosting an earnings call today at 4:30 p.m. ET. The first quarter was marked by meaningful progress. Q1 and Recent Highlights: Agreed to acquire Cancer Prevention Pharmaceuticals, Inc. (CPP). T